Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05485155 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zemaira Eosinophilic Esophagitis Pilot Study

Study acronym: ZEEPS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Oct 2025 to Oct 2026 Completion date: Jan 2026 to Jan 2027v16 Show 1 more changeShow less
    • Completion date: Jan 2026 to Jan 2027
  2. Primary completion date: Sep 2025 to Oct 2025 Completion date: Dec 2025 to Jan 2026 · Start date changed from estimate of Apr 2025 to May 15, 2025 · Site contacts updated at 1 of 2 sitesv15 Show 3 more changesShow less
    • Completion date: Dec 2025 to Jan 2026
    • Start date changed from estimate of Apr 2025 to May 15, 2025
    • Site contacts updated at 1 of 2 sites
  3. Start date: Feb 2025 to Apr 2025 Site contacts updated at 2 of 2 sitesv14 Show 1 more changeShow less
    • Site contacts updated at 2 of 2 sites
  4. Start date: Dec 2024 to Feb 2025 Eligibility criteria shortened, about 38 words · Secondary endpoints: details revised at 1 of 1 entry · Study description revisedv13 Show 3 more changesShow less
    • Eligibility criteria shortened, about 38 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  5. Primary completion date: Dec 1, 2024 to Sep 2025 Start date: Sep 1, 2024 to Dec 2024 · Completion date: Mar 1, 2025 to Dec 2025 · Eligibility criteria shortened, about 32 words · 3 morev12 Show 6 more changesShow less
    • Start date: Sep 1, 2024 to Dec 2024
    • Completion date: Mar 1, 2025 to Dec 2025
    • Eligibility criteria shortened, about 32 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
    • Site contacts updated at 2 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

Show 10 earlier versionsHide 10 earlier versions
  1. Re-verified, no change to tracked fieldsv11
  2. Start date: Mar 1, 2024 to Sep 1, 2024v10
  3. Study sites: 1 to 2v9
  4. Primary completion date: Jun 1, 2024 to Dec 1, 2024 Start date: Sep 21, 2023 to Mar 1, 2024 · Completion date: Sep 1, 2024 to Mar 1, 2025v8 Show 2 more changesShow less
    • Start date: Sep 21, 2023 to Mar 1, 2024
    • Completion date: Sep 1, 2024 to Mar 1, 2025
  5. Start date: Jun 21, 2023 to Sep 21, 2023v7
  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date: Jun 15, 2023 to Jun 21, 2023v6 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date: Jun 15, 2023 to Jun 21, 2023
  7. Start date: Apr 2023 to Jun 15, 2023 Primary completion date: May 2024 to Jun 1, 2024 · Completion date: Sep 2024 to Sep 1, 2024v5 Show 2 more changesShow less
    • Primary completion date: May 2024 to Jun 1, 2024
    • Completion date: Sep 2024 to Sep 1, 2024
  8. Start date: Jan 2023 to Apr 2023v4
  9. Start date: Oct 2022 to Jan 2023v3
  10. Primary endpoints revised (2) Eligibility criteria expanded, about 570 words · Study description expanded, about 1 wordv2 Show 2 more changesShow less
    • Eligibility criteria expanded, about 570 words
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
Trial Details
NCT Number NCT05485155
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Collaborators: CSL Behring, National Institutes of Health (NIH)
Conditions Eosinophilic Esophagitis
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov